ARTICLE | Clinical News

Ruconest conestat alfa: Phase II started

September 22, 2014 7:00 AM UTC

Pharming began a double-blind, placebo-controlled, crossover, international Phase II trial to evaluate once- or twice-weekly 50 IU/kg Ruconest for 12 weeks in about 30 HAE patients. Ruconest is approved in the U.S. and EU to treat angioedema attacks in patients with HAE. Next half, partner Salix Pharmaceuticals Ltd. (NASDAQ:SLXP, Raleigh, N.C.) plans to launch Ruconest in the U.S., where the product has Orphan Drug status for the indication. ...